Moleculin Biotech - MBRX

Call Directions Website Contact the business

Moleculin Biotech - MBRX Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Moleculin Biotech - MBRX, Biotechnology company, 5300 Memorial Drive, Suite 950, Houston, TX.

Moleculin (NASDAQ: $MBRX) is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses.

11/18/2026

South Korea's decision to grant a new patent extends Annamycin protection into another key Asia-Pacific market, reinforcing Moleculin's multi-layered patent portfolio spanning more than 20 jurisdictions as the Company's pivotal Phase 3 MIRACLE trial advances. Read more: https://bit.ly/4zPgpMn

11/18/2026

Moleculin today announced that South Korea’s Ministry of Intellectual Property has issued a decision to grant a patent covering the Company’s method of reconstituting liposomal Annamycin (also known as naxtarubicin). Read more about Moleculin's growing global patent portfolio: https://bit.ly/4zPgpMn

11/16/2026

"We are approaching one of the most important milestones in Moleculin's development, and I believe our progress has positioned us to enter 2027 with meaningful momentum," said Walter Klemp, Chairman and Chief Executive Officer of Moleculin. For recent highlights and expected milestones: https://bit.ly/4t2DkBb

At Moleculin, we are focused on advancing innovative therapies for hard-to-treat cancers.Our clinical pipeline is led by...
11/16/2026

At Moleculin, we are focused on advancing innovative therapies for hard-to-treat cancers.

Our clinical pipeline is led by Annamycin, currently being evaluated for relapsed or refractory acute myeloid leukemia.

11/16/2026

Moleculin reported on Friday the financial results for the third quarter ended September 30, 2026, and highlighted continued progress across its clinical development programs, including completion of treatment in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin (also known as naxtarubicin) in relapsed or refractory acute myeloid leukemia (AML). https://bit.ly/4t2DkBb

11/12/2026

“Securing this patent in Australia represents another step in our efforts to build a strong international intellectual property position around Annamycin,” said Walter Klemp, Chairman and CEO of Moleculin. Read more on Moleculin's growing global patent portfolio: https://bit.ly/3XmAYRS

11/12/2026

Moleculin today announced the grant of an Australian patent covering the preparation of preliposomal Annamycin lyophilizate, strengthening the Company’s intellectual property protection for a key aspect of Annamycin’s formulation technology. Read more: https://bit.ly/3XmAYRS

11/11/2026

“In April we showed Annamycin reaches pancreatic tumors in animal models and shrinks them. In September we showed the immune system is part of why. These data close the loop: when you pair Annamycin with a checkpoint inhibitor the animals live longer than with either drug alone,” said Walter Klemp, Chairman, President and CEO of Moleculin. Read his full comments on the encouraging data: https://bit.ly/4zXjIBv

11/10/2026

Annamycin achieves substantially higher pancreatic tissue exposure than doxorubicin, offering a potential explanation for why topoisomerase II, a validated target in pancreatic cancer, has never been successfully drugged there. Read more: https://bit.ly/4zXjIBv

11/10/2026

Inhibition of CD8+ T cells shortened survival in Annamycin-treated mice, demonstrating that the immune system is a functional contributor to Annamycin’s antitumor activity, not a bystander. Read more: https://bit.ly/4zXjIBv

Address

5300 Memorial Drive, Suite 950
Houston, TX
77007

Alerts

Be the first to know and let us send you an email when Moleculin Biotech - MBRX posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Moleculin Biotech - MBRX:

Shortcuts

Share

Nearby businesses